Perkins Capital Management Inc. Cuts Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Perkins Capital Management Inc. lowered its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,786 shares of the medical instruments supplier’s stock after selling 415 shares during the period. LeMaitre Vascular comprises about 2.9% of Perkins Capital Management Inc.’s portfolio, making the stock its 9th largest holding. Perkins Capital Management Inc. owned 0.15% of LeMaitre Vascular worth $3,138,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co grew its holdings in shares of LeMaitre Vascular by 44.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after acquiring an additional 6,875 shares in the last quarter. Quantbot Technologies LP grew its stake in LeMaitre Vascular by 1,001.4% in the first quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after purchasing an additional 6,669 shares in the last quarter. Quadrature Capital Ltd increased its position in shares of LeMaitre Vascular by 129.4% during the 1st quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock worth $1,484,000 after purchasing an additional 12,654 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after purchasing an additional 47,218 shares in the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $1,010,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total transaction of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Up 3.1 %

NASDAQ:LMAT opened at $101.71 on Thursday. The stock has a 50 day simple moving average of $90.13 and a 200 day simple moving average of $83.87. LeMaitre Vascular, Inc. has a 1-year low of $47.72 and a 1-year high of $103.96. The stock has a market cap of $2.29 billion, a P/E ratio of 55.58, a PEG ratio of 2.36 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. During the same quarter in the previous year, the business posted $0.33 earnings per share. LeMaitre Vascular’s quarterly revenue was up 15.6% on a year-over-year basis. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Stockholders of record on Thursday, November 21st will be issued a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 annualized dividend and a dividend yield of 0.63%. LeMaitre Vascular’s dividend payout ratio is presently 34.97%.

Analyst Upgrades and Downgrades

LMAT has been the topic of a number of recent analyst reports. JMP Securities boosted their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. Oppenheimer reiterated an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Cantor Fitzgerald began coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.